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ARTICLE
Organic Anion Transporter Polypeptide 1B1 Polymorphism 
Modulates the Extent of Drug–Drug Interaction and 
Associated Biomarker Levels in Healthy Volunteers
Sook Wah Yee1,†, Marilyn M. Giacomini2,†, Hong Shen3, W. Griffith Humphreys3, Howard Horng1, William Brian4, Yurong Lai2, Deanna 
L. Kroetz1,* and Kathleen M. Giacomini1,*
Understanding transporter- mediated drug–drug interactions is an integral part of risk assessment in drug development. Recent 
studies support the use of hexadecanedioate (HDA), tetradecanedioate (TDA), coproporphyrin (CP)- I, and CP- III as clinical bio-
markers for evaluating organic anion- transporting polypeptide (OATP)1B1 (SLCO1B1) inhibition. The current study investigated 
the effect of OATP1B1 genotype c.521T>C (OATP1B1- Val174Ala) on the extent of interaction between cyclosporin A (CsA) and 
pravastatin, and associated endogenous biomarkers of the transporter (HDA, TDA, CP- I, and CP- III), in 20 healthy volunteers. The 
results show that the levels of each clinical biomarker and pravastatin were significantly increased in plasma samples of the 
volunteers following administration of pravastatin plus CsA compared with pravastatin plus placebo. The overall fold change in 
the area under the concentration–time curve (AUC) and maximum plasma concentration (Cmax) was similar among the four bio-
markers (1.8–2.5- fold, paired t - test P value < 0.05) in individuals who were homozygotes or heterozygotes of the major allele, 
c.521T. However, the fold change in AUC and Cmax for HDA and TDA was significantly abolished in the subjects who were c.521- 
CC, whereas the respective fold change in AUC and Cmax for pravastatin and CP- I and CP- III were slightly weaker in individuals 
who were c.521- CC compared with c.521- TT/TC genotypes. In addition, this study provides the first evidence that SLCO1B1 
c.521T>C genotype is significantly associated with CP- I but not CP- III levels. Overall, these results suggest that OATP1B1 geno-
type can modulate the effects of CsA on biomarker levels; the extent of modulation differs among the biomarkers.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
☑ There is emerging interest in the use of biomarkers as 
new tools to predict transporter- mediated DDIs. Various 
endogenous metabolites have been investigated as po-
tential OATP1B1 biomarkers in clinical studies involving 
different OATP1B1/1B3 inhibitors. In addition, OATP1B1- 
Val174Ala is known to significantly affect the levels of 
these OATP1B1 metabolites. However, little is known 
about the effects of OATP1B1 genotype in modulating the 
levels of CP- I and CP- III and in modulating CsA effects on 
pravastatin drug levels and levels of various biomarkers.
WHAT QUESTION DID THIS STUDY ADDRESS?
☑ This study addresses three main questions, which were not 
previously addressed. (i) What is the impact of OATP1B1- 
Val174Ala on CP- I and CP- III levels? (ii) What is the effect of 
CsA, a nonselective OATP1B1 inhibitor, on the levels of the 
OATP1B1 biomarkers, HDA, TDA, CP- I, and CP- III? (iii) How 
does the genotype of OATP1B1 and OATP1B1- Val174Ala affect 
the extent of the OATP1B1- mediated DDI between CsA and 
pravastatin and the effect of CsA on OATP1B1 biomarkers?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
☑ This study provides further information about metabo-
lomic biomarkers of the transporter OATP1B1. In brief, we 
now know that the nonsynonymous variant in OATP1B1, 
OATP1B1- Val174, associates with plasma levels of HDA, 
TDA, and CP- I but not CP- III. We also know that the 
OATP1B1 inhibitor, CsA, significantly increases plasma 
levels of the biomarkers HDA, TDA, CP- I, and CP- III and 
that the extent of increase is modulated by the OATP1B1 
genotype.
HOW MIGHT THIS CHANGE CLINICAL 
PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
☑ This study provides critical information about the ef-
fects of an important OATP1B1 genetic polymorphism on 
the levels of biomarkers of OATP1B1 and on the effects 
of CsA inhibition of OATP1B1 on the pharmacokinetics of 
pravastatin and biomarkers of OATP1B1. Validated bio-
markers may change our ability to predict and understand 
the mechanisms of transporter- mediated clinical DDIs.
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SLCO1B1 encodes for the organic anion transporter polypep-
tide (OATP)1B1 (also known as OATP- C, OATP2, and LST- 1). 
Mainly expressed on the basolateral (sinusoidal) membrane 
of hepatocytes, the sodium- independent transporter medi-
ates the influx of various endogenous substrates, such as 
bilirubin, bile acids, conjugated steroids, and thyroid hor-
mones (see review1), as well as clinically used drugs, such 
as angiotensin- converting enzyme inhibitors, angiotensin II 
receptor antagonists, and 3- hydroxy- 3- methylglutaryl coen-
zyme A reductase inhibitors (statins).2
Pravastatin is a widely used statin that is prescribed pri-
marily for the treatment of dyslipidemia and the prevention of 
cardiovascular disease. The drug is a well- established sub-
strate of OATP1B1 and OATP1B3.3 The OATP1B1- Val174Ala 
(rs4149056, c.521T>C) polymorphism is known to have a re-
duced transporter activity, due to lower protein levels on the 
cell surface membrane.4,5 As a result, individuals with the vari-
ants have increased plasma levels of OATP1B1 substrates, for 
example, atorvastatin, rosuvastatin, and repaglinide, by ~ 1.5–
3- fold.6–9 In addition, individuals who are carriers of the variant 
also have higher levels of endogenous metabolites, which are 
OATP1B1 substrates, for example, bile acids, bilirubin, and 
fatty acid dicarboxylic acids (Table S1).10–12
Drug–drug interactions (DDIs) are common in clinical 
practice and frequently involve membrane transporters, 
such as OATP1B1. As a result, various regulatory agencies, 
such as the US Food and Drug Administration, the European 
Medicines Agency, and the Pharmaceutical and Medical 
Devices Agency in Japan have provided guidances for drug 
developers for testing new chemical entities (NCEs) in in vitro 
studies to determine their potential to cause clinically rele-
vant transporter- mediated or enzyme- mediated DDIs.13–15 
These guidances have helped drug developers enormously 
in making decisions to conduct clinical DDI studies and in 
the design of such studies. Nevertheless, there remain a 
number of false- positive and false- negative predictions re-
sulting in the conduct of unnecessary clinical studies (false- 
positives) or in failure to predict important clinical DDIs.16 
In the past several years, multiple groups, including ours, 
have evaluated the OATP1B1 endogenous metabolites, co-
proporphyrin I (CP- I), coproporphyrin III (CP- III), tetradec-
anedioic acid (TDA), hexadecanedioic acid (HDA), and bile 
acids for their sensitivity and selectivity as DDI predictive 
OATP1B1 biomarkers (Table S1).10,17–20 Importantly, the lev-
els of many of these clinical biomarkers, TDA, HDA, and 
bile acids conjugates, have been associated with SLCO1B1 
polymorphisms at genomewide significance (P < 5 × 10−8) 
in multiple studies and in several ethnic groups.21–24 In 
brief, significantly higher levels of the biomarkers are ob-
served in individuals who harbor reduced function variants 
of SLCO1B1, the gene encoding OATP1B1. These biomark-
ers have the potential for use in phase I clinical studies to 
determine whether the NCE is an in vivo OATP1B1 inhibitor. 
That is, inhibitors of OATP1B1 would phenocopy or mimic 
reduced function genetic polymorphisms, resulting in higher 
plasma levels of the biomarkers. Thus, measuring these me-
tabolites along with the NCE in early clinical studies may 
provide important in vivo information on the potential of the 
NCE to inhibit OATP1B1 and cause a DDI.
The extent of pharmacokinetic DDIs may be modulated 
by genetic variants, as has been observed in several DDI 
studies involving cytochrome P450 (CYP) enzymes. For ex-
ample paroxetine, a CYP2D6 inhibitor, increased the plasma 
concentrations of the CYP2D6 substrate, desipramine, and 
this effect was greater in CYP2D6 extensive metabolizers 
than in poor metabolizers.25 Although fewer, similar ob-
servations have been made about the extent of DDIs with 
polymorphisms in transporters. For example, the extent of 
modulation of OATP1B1 genotype on interactions between 
gemfibrozil and repaglinide, rifampicin and atorvastatin, cy-
closporin A (CsA) and repaglinide, and darunavir/ritonavir 
and pravastatin has been characterized for the OATP1B1- 
Val174Ala (SLCO1B1 c.521T>C ) variant.8,26–28 These studies 
are consistent with studies of CYPs and, in general, show 
that reduced function polymorphisms attenuate the extent 
of the interaction. To date, only one study has evaluated the 
effect of homozygotes for SLCO1B1 c.521T>C (phenotype 
with poor transporter activity) on both a clinical DDI and the 
levels of an OATP1B1 biomarker in the presence of a perpe-
trator of a DDI.
The goal of this study was to determine the influence 
of the common OATP1B1 functional variant c.521T>C 
(rs4149056) on OATP1B1/1B3- mediated CsA inhibition 
of pravastatin and four previously documented OATP1B1 
biomarkers: HDA, TDA, CP- I, and CP- III (Table S1). Using 
a cohort of healthy volunteers with known SLCO1B1 gen-
otype c.521T>C (rs4149056), we determined the extent of 
CsA interaction on pravastatin disposition and also its ef-
fect on the four clinical biomarkers. Consistent with previous 
studies,29,30 pravastatin levels as well as levels of biomarker 
were increased in the presence of CsA. Notably, the effect 
of c.521T>C in modulating the CsA- dependent increases in 
biomarker levels was dependent on the individual biomarker.
METHODS
Clinical study
A blinded, randomized, two- treatment crossover study was 
conducted on 20 healthy, white volunteer subjects selected 
for the SLCO1B1 c.521T>C genotype (rs4149056; Val174Ala) 
at the University of California, San Francisco Clinical and 
Translational Science Institute Clinical Resources Services 
(NCT01497483). To be eligible for the study, subjects had to 
provide written informed consent, be between the ages of 
18 and 45 years, be in good health (as evidenced by medi-
cal histories, physical examination, and routine clinical lab-
oratory evaluations), not be on any medications other than 
oral contraceptives, and not have any known allergies to 
pravastatin or CsA. Subjects were admitted to the clinical 
facility the evening before and remained onsite for the du-
ration of the study (24 hours). The evening before the study, 
each study participant received either placebo or CsA 
(100 mg). Study participants then fasted for at least 10 hours 
before receiving another dose of placebo or CsA (100 mg) 
the next morning. One hour after the second dose of pla-
cebo or CsA, participants were given a single 40 mg dose 
of pravastatin. Plasma samples were obtained at baseline 
and at various times for 12 hours. Each study participant 
received both treatments that included a washout period of 
at least 2 weeks in between treatments. Plasma pravastatin 
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concentrations were determined by high- performance liq-
uid chromatography–tandem accurate mass spectrometry. 
The liquid chromatography–tandem mass spectrometry 
analysis of pravastatin, TDA, HDA, CP- I, and CP- III are 
available in the Supplemental Material section.
Genotyping of SLCO1B1 c.521T>C (rs4149056)
Genomic DNA samples from 186 unrelated European- 
Americans of the San Francisco Bay Area (part of the 
Studies of Pharmacogenetics in Ethnically Diverse 
Populations cohort) were obtained and genotyped for the 
single nucleotide polymorphism rs4149056 (SLCO1B1 
c.521T>C). A TaqMan single nucleotide polymorphism ge-
notyping assay (assay ID C__30633906_10) was used for 
genotyping on the ABI 7900 Fast HT Sequence Detection 
Systems (Applied Biosystems, Foster City, CA). Genomic 
DNA (10 ng) was amplified using a TaqMan Genotyping 
Master Mix (Applied Biosystems). The polymerase chain 
reaction conditions were as follows: 1 cycle of 95°C for 
10 minutes followed by 40 cycles of two- step polymerase 
chain reaction with denaturation at 95°C for 15 seconds 
and annealing and extension at 60°C for 1.5 minutes. Data 
were analyzed by allele discrimination.
Statistical analysis
The results are expressed as mean values ± SD in the text 
and tables and as mean values ± SEM in the figures. The 
maximum plasma concentration (Cmax) and area under the 
concentration–time curve (AUC) data were obtained using 
Phoenix WinNonlin 6.4. (Certara USA, Princeton, NJ) before 
the statistical analysis. Statistical comparisons of pharma-
cokinetic parameters between subjects with the c.521- TT, 
TC, and CC genotypes during the three treatment phases 
were carried out using repeated- measures analysis of vari-
ance (ANOVA) with treatment phase as a within- subjects 
factor and genotype group as a between- subjects factor. 
A priori testing between genotypes during each treatment 
phase was carried out using the Fisher’s least significant 
difference method and between phases within each gen-
otype group using the paired t - test. The pharmacokinetic 
variables of pravastatin and the four endogenous metab-
olites were compared between the genotype groups using 
ANOVA or Student’s t - test if comparing two genotype 
groups (c.521- TT/TC vs. c.521- CC). The statistical analysis 
was performed using Prism 7 (GraphPad, San Diego, CA). 
Differences were considered statistically significant when P 
value was < 0.05.
RESULTS
Clinical cohort
Eleven men (SLCO1B1 c.521T>C, N = 5 TT, 5 TC, 1 CC) and 
nine women (SLCO1B1 c.521T>C, N = 4 TT, 3 TC, 2 CC) 
participated in the clinical studies (Table S2). For the clini-
cal biomarker studies, only 16 individuals (8 with c.521TT, 6 
with c.521TC, and 2 with c.521CC) who had sufficient sam-
ples to measure the four metabolites (TDA, HDA, CP- I, and 
CP- III) were included in the analyses for metabolites–CsA 
interaction (Table S2).
Plasma pravastatin levels were increased following 
CsA administration in noncarriers and carriers of the 
SLCO1B1 c.521T>C allele
To determine the effects of CsA on pravastatin disposi-
tion, we examined the plasma pravastatin levels after pla-
cebo or CsA administration from 0−12 hours in 20 healthy, 
white volunteers (Figure 1a). The mean AUC0→12 (AUClast) 
of pravastatin was significantly greater following admin-
istration of CsA (554 ± 380 ng·hour/mL) compared with 
placebo (162 ± 129 ng·hour/mL; Figure 1b, Table 1). The 
mean Cmax of pravastatin was also significantly higher 
following administration of CsA (339 ± 266 ng/mL) com-
pared with placebo (106 ± 100 ng/mL; Figure 1c, Table 1). 
Furthermore, the volume of distribution and clearance for 
orally administered pravastatin were significantly different 
Figure 1 Plasma concentration–time profiles and pharmacokinetic parameters of pravastatin in healthy volunteers following 
administration of pravastatin plus placebo and pravastatin plus cyclosporin A (CsA). (a) Pravastatin plasma concentration–time profile 
in each treatment group (mean ± SEM); (b) pravastatin area under the concentration–time curve from time of administration up to 
the time of the last quantifiable concentration (AUC0–last(0–12 hour)); and (c) peak plasma concentration (Cmax) of each individual in the 
pravastatin plus placebo and pravastatin plus CsA group.
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in the placebo and CsA treatment groups (Table 1). Similar 
effect was also observed when we examined the Cmax and 
AUClast of the pravastatin isomer 3′α- hydroxy- pravastatin 
peak only or pravastatin peak only without the isomer 
(Figure S1, Table S3). The pravastatin concentration–
time profile for each genotype group following pravas-
tatin and placebo or CsA administration is shown in 
Figure 2a. Although the AUC0→12 and Cmax of pravasta-
tin in individuals who were homozygous carriers of the 
c.521- CC were greater than the corresponding values for 
the other genotype groups, they were not statistically sig-
nificant using ANOVA or Kruskal–Wallis tests (AUC0→12: 
c.521- TT = 154 ± 153 ng/mL, TC = 124 ± 58 ng/mL, 
CC = 290 ± 148 ng/mL; Cmax: c.521- TT = 98.8 ± 114 ng/
mL, TC = 79.1 ± 50 ng/mL, CC = 201 ± 136 ng/mL; see 
Table 1). On the other hand, when we examined the pravas-
tatin peak only, there were statistically significant results 
using ANOVA test among the three genotype groups 
(AUC0→12: c.521- TT = 43 ± 15 ng/mL, TC = 48 ± 23 ng/
mL, CC = 154 ± 147 ng/mL; Cmax: c.521- TT = 22 ± 9.3 ng/
mL, TC = 31 ± 19 ng/mL, CC = 111 ± 126 ng/mL; see 
Table S3). Notably, the 3′α- hydroxy- pravastatin peak only 
was not statistically significant among the three geno-
type groups (Figure S1, Table S3). Figure 2b shows the 
AUC0→12 and Cmax of individuals upon administration of 
placebo or CsA separated by genotype group. CsA ad-
ministration resulted in increased AUC0→12 and Cmax in 
all c.521T>C groups (Figure 2b, Table 1). Although the 
mean fold change of both AUC0→12 and Cmax was reduced 
in carriers of the SLCO1B1 c.521T>C allele compared 
with those with the reference allele, the paired t - tests 
were significant except AUC0→12 in carriers of the homo-
zygous SLCO1B1 c.521T>C allele (Table 1, Figure 2d). 
Similar trend is also observed when we examined the 3α- 
hydroxy- pravastatin peak only or pravastatin peak only, 
where the mean fold change of both AUC0→12 and Cmax 
was reduced in carriers of the SLCO1B1 c.521T>C allele 
compared with those with the reference allele (Figure S1, 
Table S3). Overall, the ratio of mean AUC0→12 in SLCO1B1 
c.521CC and SLCO1B1 c.521TT were 1.9, 3.6, and 1.2 
for combined pravastatin and 3α- hydroxy- pravastatin, 
pravastatin only, and 3α- hydroxy- pravastatin only, respec-
tively (Table S3). Pravastatin is extensively metabolized 
to the 3α- hydroxy isomer, which has one- tenth to one- 
fortieth of the inhibitory activity of the parent compound 
on 3- hydroxy- 3- methylglutaryl coenzyme A reductase.31
Plasma HDA, TDA, CP- I, and CP- III levels were 
increased following CsA administration
Plasma concentration–time profile of the four biomarkers, 
HDA, TDA, CP- I, and CP- III, showed increased levels after 
pravastatin plus CsA administration compared with pravastatin 
plus placebo administration (Figure 3a, Table 2). After admin-
istration of CsA plus pravastatin, average plasma concentra-
tion (Cavg), Cmax, and AUClast(0.25–12 hour)) of the four biomarkers, 
HDA, TDA, CP- I, and CP- III, increased 1.8–2.1- fold, 1.9–2.2- 
fold, 1.7–2.2- fold, and 1.5–1.9- fold in comparison to the pla-
cebo plus pravastatin period, respectively. All increases were 
statistically significant (P < 0.05, paired t - test) (Table 2). The 
mean C0 (plasma levels 12 hours after the first dose of CsA or 
placebo and right before the second dose of CsA or placebo) 
of HDA was significantly higher (Table 2). For TDA, the mean 
C0 also increased significantly (P < 0.05), but only after data 
from the two subjects who were homozygous for the minor 
allele c.521- CC were removed from the analysis (Table 3). In 
contrast, CP- I and CP- III at baseline (C0) were below the levels 
of quantification for 12 of 16 samples and only reached mea-
surable levels at 15 minutes (or later) after CsA administration. 
In addition, correlation analysis showed that the pravastatin 
AUC significantly correlates (P < 0.005) with each of the bio-
markers (Figure 4, Table S3). Overall, the magnitude of the 
fold increase in Cavg and Cmax for HDA, TDA, and CP- I were 
similar and greater than that of CP- III, whereas the magnitude 
of AUClast was similar across the four metabolites (Table 2).
Plasma HDA, TDA, and CP- I levels were increased in 
carriers of the SLCO1B1 c.521T>C allele
Results comparing the plasma concentration–time curves 
of the four biomarkers and the Cavg and AUClast(0.25–12 hour) 
for each of the biomarkers are shown in Figure 3b and 
Table 3. After administration of placebo plus pravastatin, the 
Cavg and AUClast of HDA, TDA, and CP- I were significantly 
Table 1 Influence of cyclosporin A and SLCO1B1 c.521T>C genotype on the pharmacokinetics of pravastatin in volunteers
Treatment Pravastatin + placebo Pravastatin + cyclosporine
Genotype All genotype TT (N = 9) TC (N = 8) CC (N = 3) All genotype TT (N = 9) TC (N = 8) CC (N = 3)
t1/2 (hour) 1.12 ± 0.65 1.16 ± 0.82 1.21 ± 0.56 0.76 ± 0.25 0.87 ± 0.27 0.90 ± 0.26 0.84 ± 0.34 0.88 ± 0.08
Tmax (hour) 1.05 ± 0.36 1.00 ± 0.40 1.09 ± 0.35 1.08 ± 0.38 1.25 ± 0.56 1.25 ± 0.57 1.16 ± 0.60 1.50 ± 0.5
Cmax (ng/mL) 106 ± 100 98.8 ± 114 79.1 ± 50.0 201 ± 136 339 ± 266**** 
(4.3)
364 ± 360* 
(5.3)
266 ± 153* 
(3.9)
458 ± 166* 
(2.6)
AUClast (ng·hour/mL) 162 ± 129 154 ± 153 124 ± 58.0 290 ± 148 554 ± 380**** 
(4.2)
572 ± 488* 
(5.0)
436 ± 198** 
(3.8)
818 ± 351 
(3.1)
V/F (L/kg) 8.39 ± 8.39 9.56 ± 8.74 9.49 ± 9.08 1.94 ± 1.37 1.60 ± 1.02** 1.92 ± 1.34* 1.52 ± 0.54* 0.85 ± 0.70*
CL/F (L/hour/kg) 5.17 ± 4.44 6.12 ± 5.34 5.42 ± 3.77 1.65 ± 0.68 1.34 ± 0.85*** 1.47 ± 0.98* 1.45 ± 0.74* 0.64 ± 0.48
Pharmacokinetic parameters of pravastatin when administered with placebo and cyclosporin A (CsA) are shown. Data are presented as mean ± SD for each 
genotype group and all subjects combined. Paired t - test was used to determine the significance of each pharmacokinetic parameter between the treatment 
groups. The numbers in the parentheses represent the fold increase of pravastatin levels in pravastatin and CsA group over pravastatin + placebo.
AUClast, area under the curve from time zero to the last quantifiable concentration (12 hour); CL/F, apparent oral clearance (F is oral bioavailability) based on 
dose divided by AUClast; Cmax, peak plasma concentration; t1/2, half- life; Tmax, time to reach peak plasma concentration; V/F, apparent volume of distribution.
The significant P values are: *P < 0.05; **P < 0.005; ***P < 0.0005; and ****P < 0.0001.
5www.cts-journal.com
OATP1B1 Polymorphism and Biomarker Levels
Yee et al.
Figure 2 The effect of cyclosporin A (CsA) administration on plasma levels of pravastatin in volunteers from three different genotype 
groups: SLCO 1B1 c.521 TT , SLCO 1B1 c.521 TC , and SLCO 1B1 c.521 CC (TT, TC, and CC). (a) Plasma concentration–time profiles of 
pravastatin following placebo administration in the three different SLCO 1B1 c.521T>C genotype groups. (b) Plasma concentration–time 
profiles of pravastatin following placebo or CsA administration in the three different SLCO 1B1 c.521T>C genotype groups. Data in a and 
b are presented as mean ± SEM. (c) Pravastatin area under the concentration–time curve from time of administration up to the time of 
the last quantifiable concentration (AUC0–last(0–12 hour)) and peak plasma concentration (Cmax) for each individual following placebo or CsA 
administration in the three different SLCO 1B1 c.521T>C genotype groups. Each line connects data in the same individual who participated 
in the crossover study. (d) Fold increase in pravastatin AUC0–last(0–12 hour) and Cmax in the three different SLCO 1B1 c.521T>C genotype 
groups. Fold increase is calculated by dividing the parameters from the pravastatin plus CsA group with pravastatin plus placebo group.
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different among the three genotype groups, c.521- TT, TC, 
and CC. In contrast, CP- III Cavg and AUClast were similar 
among the genotype groups (Table 3, Figure 3b, Figure 
S2). One unexpected observation is noted in Figure 3a,b. 
That is, levels of CP- I and CP- III did not change following 
administration of pravastatin plus placebo; however, the 
plasma concentrations of HDA and TDA in individuals who 
were homozygous for the c.521- CC increased by at least 
twofold (Cmax over baseline) and peaked at around 3 hours 
(Figure 3a,b, Figure S2).
The extent of fatty acid dicarboxylic acid–CsA 
interaction, but not CP- I interaction, was reduced in 
carriers of the SLCO1B1 c.521T>C allele
Figure 3c–e and Table 3 show the results comparing the 
plasma concentration–time curves and the Cavg and AUClast 
of the four biomarkers. We determined whether SLCO1B1 
c.521T>C genotype modulated the effect of CsA on the lev-
els of the four metabolites by comparing change in base-
line, Cavg, and AUClast of the metabolites among the three 
genotype groups following CsA (plus pravastatin) admin-
istration. Figure 3c–e shows that the fold change in HDA 
and TDA Cavg and AUClast following CsA administration 
was small in the two individuals who were c.521- CC. That 
is, the change in Cavg was 1.2 and 0.9 for HDA and TDA, 
respectively, and for AUClast it was identical, 1.2 and 0.9 for 
HDA and TDA, respectively. In contrast, greater changes 
were observed in both Cavg and AUClast following CsA 
administration in the individuals who were c.521- TT and 
c.521- TC (Table 3). Importantly, the paired t - test P value 
for the effect of CsA on Cavg and AUClast were more signif-
icant when individuals who were c.521- CC were excluded 
from the analysis (Table 3). In contrast, Cavg and AUClast of 
CP- I and CP- III were increased upon CsA administration 
in all three genotype groups. Although the fold change is 
reduced in individuals with c.521- CC, the paired t - test P 
values remained similar whether or not the c.521- CC was 
excluded (Table 3).
Pravastatin AUC correlates significantly with AUC of 
all four biomarkers
Pearson’s correlation analysis showed that pravastatin 
AUC positively correlates (P < 0.05) with all biomarkers 
(Figure 4a, Table S4). When individual with SLCO1B1 
c.521- CC were removed, the AUC correlation remained 
significant, except with CP- I (P = 0.10; Figure 4b). Notably, 
when one individual who had the highest pravastatin AUClast 
(in both placebo and CsA group) was removed from the 
correlation analysis, the correlation of pravastatin AUC with 
each of the four biomarkers became significant (P < 0.05).
Figure 3 Plasma levels of organic anion- transporting polypeptide (OATP)1B1 biomarker in carriers of the SLCO 1B1 c.521T>C allele 
and the influence of SLCO 1B1 c.521T>C genotype on OATP1B1 biomarker levels and on the effects of cyclosporin A (CsA). Plasma 
concentration–time profiles of the four OATP1B1 biomarkers in (a) pravastatin plus placebo and pravastatin plus CsA administration; in 
(b) pravastatin plus placebo administration separated by SLCO 1B1 c.521T>C genotype; in (c) pravastatin plus placebo and pravastatin 
plus CsA administration separated by SLCO 1B1 c.521T>C genotype. OATP1B1 biomarkers (d) area under the concentration–time 
curve from time of administration up to the time of the last quantifiable concentration (AUC0–last (0–12 hour)) and (e) Cmax of each individual 
Table 2 Levels of the four OATP1B1 biomarkers, HDA, TDA, CP- I, and CP- III, in each treatment group
Treatment Pravastatin + placebo (N = 16) Pravastatin + cyclosporine (N = 16)
Biomarker HDA TDA CP- I CP- III
HDA (fold 
change)
TDA (fold 
change)
CP- I (fold 
change)
CP- III (fold 
change)
C0 (nM) 60.1 ± 37 55 ± 44 
[N = 11]
BLOQ in 
most 
samples
BLOQ in 
most 
samples
84 ± 33 ** 
[N = 11] (1.5)
68 ± 26 
[N = 11] 
(1.6)
BLOQ in most 
samples
BLOQ in most 
samples
Cmax (nM) 90.6 ± 77.3 94.7 ± 118.5 1.04 ± 0.45 0.15 ± 0.039 155 ± 55.1** 
(2.1)
149 ± 71.0* 
(2.2)
2.16 ± 0.71**** 
(2.2)
0.24 ± 0.05**** 
(1.7)
Cavg (nM) 56.4 ± 35.1 53.3 ± 49.3 0.83 ± 0.36
a0.12 ± 0.03 100 ± 33.3**** 
(2.0)
86.0 ± 35.8** 
(2.0)
1.51 ± 0.56**** 
(1.9)
a0.17 ± 0.03**** 
(1.5)
AUClast (nM·hour) 649 ± 346 593 ± 489 9.4 ± 4.2
a1.21 ± 0.46 1,070 ± 357**** 
(1.8)
902 ± 378** 
(1.9)
15.5 ± 6.7**** 
(1.7)
a1.68 ± 0.44*** 
(1.9)
Arithmetic mean ± SD for each biomarker’s parameters in the two treatment groups are reported in this table. Paired t - test was used to determine the signifi-
cance of each parameter between the treatment groups. Number in parentheses is the fold increase between pravastatin plus cyclosporin A group over 
pravastatin plus placebo group. A total of 16 subjects were available for biomarker analysis; however, for some biomarkers, the levels are below the level of 
quantification; the number in square brackets is number of subjects available for the analysis.
AUClast, area under the curve from time 15 minutes after second dose of cyclosporin A administration or placebo to 12 hours; BLOQ, below the limit of quan-
tification; C0, concentrations at time 0, baseline (this level is taken after 12 hours from cyclosporin A administration from the night before and right before the 
second dose of cyclosporin A administration); Cavg, average concentrations from the collected samples, 15 minutes after second dose of placebo or cyclo-
sporin A administration; Cmax, maximum concentrations from the collected samples, 15 minutes after second dose of placebo or cyclosporin A administra-
tion; CP, coproporphyrin; HDA, hexadecanedioate; OATP, organic anion- transporting polypeptide; TDA, tetradecanedioate.
aOverall, CP- III are very low and many timepoints have below quantification levels.
The significant P values are: *P < 0.05; **P < 0.005; ***P < 0.0005; ****P < 0.0001.
in the pravastatin plus placebo and pravastatin plus CsA group separated by SLCO 1B1 c.521T>C genotype (TT, TC, and CC). Each line 
connects the same individual who did the crossover study. Data in a–c are presented as mean ± SEM. Solid lines in c represent levels 
from pravastatin plus placebo administration and dashed lines represent levels from pravastatin plus CsA administration. Cavg, average 
plasma concentration; Cmax, peak plasma concentration; CP, coproporphyrin; HDA, hexadecanedioate; TDA, tetradecanedioate.
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Table 3 Levels of the OATP1B1 biomarkers, HDA, TDA, CP- I, and CP- III, in each genotype and treatment group
Treatment Pravastatin + placebo [N = 16] Pravastatin + cyclosporine [N = 16] aPaired 
t- test, P 
value 
(only TT/
TC)HDA All genotype TT (N = 8) TC (N = 6) CC (N = 2) All genotype TT (N = 8) TC (N = 6) CC (N = 2)
C0 (nM) 60.1 ± 37.0*
,b 
[N = 11]
52.0 ± 29.6 
[N = 5]
43.1 ± 13.4 
[N = 4]
114 ± 47.5 
[N = 2]
84 ± 33 [N = 11] 
(1.5)
84.6 ± 39.1**,c 
[N = 5] (1.7)
70.3 ± 23.4*,c 
[N = 4] (1.6)
111 ± 34.6 
[N = 2] 
(1.0)
0.0009 
(2.8E- 5)
Cavg (nM) 56.4 ± 35.1****
,b 46.1 ± 14.3 44.0 ± 11.5 135 ± 46.6 100 ± 33.3 (2.0) 98.5 ± 27.8***,c 
(2.2)
86.9 ± 33.0*,c 
(2.0)
149 ± 5.0 
(1.2)
2.1E- 5 
(5.2E- 6)
AUClast 
(nM·hour)
649 ± 346****,b 557 ± 161 506 ± 116 1,450 ± 299 1,070 ± 357*,b 
(1.8)
1,070 ± 239***,c 
(2.0)
853 ± 303*,c 
(1.7)
1,680 ± 148 
(1.2)
1.9E- 5 
(1.8E- 5)
TDA All genotype TT (N = 8) TC (N = 6) CC (N = 2) All genotype TT (N = 8) TC (N = 6) CC (N = 2)
aPaired 
t- test 
P- value 
(only TT/
TC)
C0 (nM) 55 ± 44**
,b 
[N = 11]
44 ± 24.5 
[N = 5]
31.3 ± 5.0 
[N = 4]
131 ± 48.9 
[N = 2]
68 ± 26*,b 
[N = 11] 
(1.6)
77.7 ± 22.0**,c 
[N = 5] 
(2.1)
44.2 ± 14.8 
[N = 4] 
(1.4)
91.3 ± 23.9 
[N = 2] 
(0.7)
0.20 
(0.002)
Cavg (nM) 53.3 ± 49.3****
,b 38 ± 13.7 34.6 ± 10.4 171 ± 53.7 86.0 ± 35.8*,b
(2.0)
87.6 ± 29.5**,c
 (2.5)
64.5 ± 26.4*,c
 (1.8)
144 ± 13.9 
(0.9)
0.003 
(2.5E- 5)
AUClast 
(nM·hour)
593 ± 489****,b 448 ± 153 386 ± 84 1,800 ± 237 902 ± 378**,b
(1.9)
927 ± 282**,c
(2.2)
652 ± 246*,c
 (1.7)
1,550 ± 249 
 (0.9)
0.0025 
(6.0E- 5)
CP- I All genotype TT (N = 8) TC (N = 6) CC (N = 2) All genotype TT (N = 8) TC (N = 6) CC (N = 2)
aPaired 
t- test 
P- value 
(only TT/
TC)
Cavg (nM) 0.83 ± 0.36****
,b 0.6 ± 0.1 0.88 ± 0.26 2.19 ± 0.64 1.51 ± 0.56**,b
 (1.9)
1.15 ± 0.28***,c
 (1.9)
1.67 ± 0.33***,c
 (2.0)
2.50 ± 0.68 
 (1.6)
5.0E- 8 
(2.2E- 7)
AUClast 
(nM·hour)
9.4 ± 4.2***,b 6.9 ± 1.2 9.8 ± 3.3 17.8 ± 3.2 15.5 ± 6.7**,b
 (1.7)
11.8 ± 2.3***,c
 (1.7)
16.5 ± 5.7***,c
 (1.7)
27.6 ± 8.4 
 (1.5)
2.7E- 6 
(8.3E- 6)
CP- III All genotype TT (N = 8) TC (N = 6) CC (N = 2) All genotype TT (N = 8) TC (N = 6) CC (N = 2)
aPaired 
t- test 
P- value 
(only TT/
TC)
dCavg (nM) 0.12 ± 0.03 0.11 ± 0.02 0.11 ± 0.03 0.15 ± 0.004 0.17 ± 0.03*
,b
 (1.5)
0.15 ± 0.03**,c
 (1.4)
0.18 ± 0.02**,c
 (1.7)
0.21 ± 0.008*,c
 (1.3)
1.2E- 6 
(1.3E- 5)
dAUClast 
(nM·hour)
1.21 ± 0.46 1.2 ± 0.17 1.0 ± 0.68 1.7 ± 0.013 1.68 ± 0.44 
(1.9)
1.56 ± 0.24**,c
(1.3)
1.65 ± 0.60*,c
(3.0)
2.22 ± 0.13 
(1.2)
0.0001 
(0.0006)
Arithmetic mean ± SD for each biomarker’s parameters in the two treatment groups are reported in the table. Paired t - test was used to determine the signifi-
cance of each parameter between the treatment groups. Possible associations of SLCO1B1 c.521T>C with biomarkers in the pravastatin plus placebo group 
were investigated by use of analysis of variance. Differences were considered statistically significant at P < 0.05. The fold increase between pravastatin + cy-
closporin A (CsA) group over pravastatin + placebo group is shown in the table. The number in parentheses is the fold increased between pravastatin plus 
CsA group over pravastatin plus placebo group for each genotype group. A total of 16 subjects were included in the biomarker analysis; however, for some 
biomarkers, the levels were below the level of quantification; the number in square brackets is the number of subjects available for the analysis. See footnote 
below for the different statistical analyses performed.
AUClast, area under the curve from time 15 minutes after second dose of CsA administration or placebo to 12 hours; C0, concentrations at time 0, baseline 
(this level is taken 12 hours after the first CsA dose and right before the second dose of CsA); Cavg, average concentrations from the collected samples, 
15 minutes after second dose of placebo or CsA administration; CP, coproporphyrin; HDA, hexadecanedioate; OATP, organic anion- transporting polypep-
tide; TDA, tetradecanedioate.
aPaired t - test to test whether there were significant differences between the individuals in the two treatment groups. The P value for significance including 
all genotype groups and the P value for significance including the SLCO1B1 c.521T>C, TT, and TC groups are shown in the parentheses. bAnalysis of variance 
(ANOVA) was used to test whether the three genotype groups’ means are all equal. Possible associations of SLCO1B1 c.521T>C with biomarkers in the 
pravastatin plus placebo group were investigated by use of ANOVA. The P values for significance are *P < 0.05; **P < 0.005; ***P < 0.0005; and ****P < 0.0001.
cPaired t - test to test whether there were significant differences between the individuals in the two treatment groups with the same genotype group. The P 
values for significance are *P < 0.05; **P < 0.005; *** P < 0.0005; and **** P < 0.0001. dOverall, CP- III are very low and many time points have below quantifi-
cation levels.
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Figure 4 Correlation between pravastatin area under the concentration–time curve from time of administration up to the time of the 
last quantifiable concentration (AUClast) and each of the biomarkers in pravastatin plus placebo group (solid circles) and pravastatin 
plus cyclosporin A (CsA) group (open circles). Correlation in (a) individual irrespective of SLCO 1B1 c.521T>C genotype and (b) individual 
with SLCO 1B1 c.521- TT or c.521- TC genotype. The correlation, r , and P value for the Pearson’s correlation is shown in the figure and 
in Table S4. CP, coproporphyrin; HDA, hexadecanedioate; TDA, tetradecanedioate.
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DISCUSSION
Clinical DDIs contribute to drug toxicities by increasing sys-
temic or tissue- specific levels of drugs. Thus, in order to 
ensure patient safety, regulatory agencies require that all 
new drug applications include information on DDI liabilities. 
For new drugs that are shown in in vitro transporter studies 
to be substrates or inhibitors of major transporters in the 
liver and/or kidneys, clinical DDI studies may be required to 
determine the effect of the drug candidates on co adminis-
tered drugs or vice versa. To enhance the ability to predict 
clinical DDIs and reduce false- positive and false- negative 
results, other tools are needed in addition to in vitro trans-
porter assays. A number of groups have explored the use 
of endogenous metabolites as biomarkers of transporter- 
mediated DDIs in early clinical studies (Table S1). In this 
study, we further characterized four endogenous metabo-
lites that have been previously identified as potential bio-
markers of OATP1B1 inhibition. The goal of our study was 
to assess the effect of a reduced function genetic variant in 
SLCO1B1 (c.521T>C) in association with baseline levels and 
modulating the effects of CsA on the levels of the four me-
tabolites as well as on pravastatin pharmacokinetics. Our 
study revealed four major findings. First, the effect of CsA 
on pravastatin pharmacokinetics was reduced in individuals 
who were homozygous for c.521C in comparison with het-
erozygotes and individuals homozygous for the reference 
allele, c.521T. Second, baseline levels of CP- I, but not CP- 
III, were associated with the SLCO1B1 c.521T>C genotype. 
Third, CsA plus pravastatin did not significantly increase the 
levels of HDA and TDA over pravastatin plus placebo in the 
individuals who were homozygous for SLCO1B1 c.521C; 
however, levels of CP- I and CP- III increased following CsA 
administration in all genotype groups. Finally, the pravasta-
tin AUClast correlated significantly with all four biomarkers. 
Below, we discuss the four major findings in the context of 
the literature.
Our first finding, that CsA increased pravastatin plasma 
concentrations in accordance with SLCO1B1 c.521T>C 
genotype, was not unexpected. First, CsA has been found 
to increase pravastatin levels in previous studies in trans-
plant patients.29,30 Second, pharmacogenetic studies have 
revealed that pravastatin levels are significantly higher in 
patients who are homozygous for SLCO1B1 c.521T>C.32,33 
A few studies have determined the effect of SLCO1B1 
c.521T>C genotype on OATP1B1- mediated DDIs (see Table 
S5). To our knowledge, this is the first report to show the 
effect of genotype in modulating an OATP1B1- mediated 
DDI with pravastatin. We rationalized that if the transporter 
activity is already substantially reduced by the genetic poly-
morphism, CsA will not be able to further reduce the ac-
tivity. Our study with pravastatin and CsA demonstrated 
similar SLCO1B1 genotype effects with a published study 
of atorvastatin and rifampicin.8 That is, the effects of perpe-
trator (OATP1B1 inhibitor, CsA, or rifampicin) on victim drug 
(pravastatin or atorvastatin) plasma levels are much lower 
in individuals who are homozygous for the reduced func-
tion variant, c.521T>C, in comparison with heterozygotes or 
 individuals who were homozygous for the reference allele. As 
CsA (or rifampicin) is not a selective inhibitor for OATP1B1 
and also inhibits OATP1B3 and other hepatic transporters, 
such as OATP2B1,34 the data suggest that OATP1B1 is a 
major CsA sensitive influx transporter for pravastatin in the 
liver. If other CsA sensitive transporters were significantly in-
volved in pravastatin hepatic uptake, then CsA would have 
provided additional inhibitory effects in individuals homo-
zygous for the reduced function OATP1B1 variant. For ex-
ample, following administration of gemfibrozil, the AUC of 
repaglinide increased more in subjects who were SLCO1B1 
c.521- CC than in subjects who were SLCO1B1 c.521- TT.28
Our second finding, that baseline levels of CP- I but not 
CP- III were associated with SLCO1B1 c.521T>C genotype, 
was somewhat surprising, and suggests that there may be 
quantitative differences in the influx pathways of the two 
metabolites. Recent study from Mori et al. 35 also showed 
that CP- I level was significantly associated with SLCO1B1 
c.521T>C. Previously, we have shown that HDA and TDA 
are substrates of OATP1B1 and their levels are signifi-
cantly higher in individuals who are carriers of c.521T>C.10 
Accordingly, because our previous studies demonstrated 
that CP- I and CP- III are substrates of OATP1B136 (Table 
S1), we would have expected that levels of both of these 
metabolites would be elevated in individuals who carried 
the reduced function allele of SLCO1B1 (Figure 3). It was 
previously shown that patients with Rotor’s syndrome, who 
have deletions in SLCO1B1 and SLCO1B3 , have greater uri-
nary excretion rates of CP- I.37,38 Our finding that CP- III lev-
els were not sensitive to SLCO1B1 genotype suggests that 
other transporters (or pathways) may be involved in its he-
patic uptake. Indeed, in vitro studies showed the CP- III, but 
not CP- I, is a substrate of OATP2B1.36 The observation that 
there was a trend toward elevated CP- III levels in the two 
individuals with a c.521- CC genotype (Figure 3, Table 3) 
is consistent with the notion that OATP1B1 plays at least a 
minor role in the hepatic uptake of CP- III. Our observations 
are also supported by studies in patients with Rotor’s syn-
drome (i.e., CP- III excretion rates are either mildly increased 
or not increased in patients with Rotor’s syndrome, whereas 
CP- I excretion rates are increased significantly; Wolkoff 
et al. 38 and Shimidzu et al. 37). Overall, the ratio of mean AUC 
in SLCO1B1 c.521- CC to c.521TT were 2.6, 4.0, and 2.6 for 
HDA, TDA, and CP- I, respectively, similar to the correspond-
ing values of pravastatin plus 3α- hydroxy pravastatin peaks 
(1.9- fold) and of pravastatin peak only (3.6- fold).
Our third finding was that CsA plus pravastatin did not 
significantly increase the levels of HDA and TDA in the in-
dividuals who were homozygous for SLCO1B1 c.521C in 
comparison to pravastatin plus placebo; however, levels 
of CP- I and CP- III increased following CsA administration 
in all genotype groups. These differences in the effects of 
OATP1B1 genotype in modulating the inhibitory effects of 
CsA and even pravastatin itself on the levels of the biomark-
ers suggest differences in the importance of OATP1B1 in 
the kinetics of the individual biomarkers. Interestingly, HDA 
and TDA levels increased after pravastatin plus placebo 
administration, but only in the two individuals who had the 
SLCO1B1 c.521- CC genotype. In these same two individ-
uals, HDA and TDA levels did not increase further following 
11
www.cts-journal.com
OATP1B1 Polymorphism and Biomarker Levels
Yee et al.
CsA plus pravastatin administration (Figure 3b–e, Figure 
S2). These data are consistent with the idea that pravas-
tatin may have maximally inhibited the residual transport 
activity of OATP1B1 in the individuals who are homozygous 
for the reduced function allele. Thus, CsA plus pravastatin 
was not able to further affect the levels of the two metabo-
lites over pravastatin alone. Notably, Figures 2a,b and 3a,b 
showed that HDA and TDA levels in the two individuals who 
are c.521- CC peaked after levels of pravastatin increased 
(time to maximum concentration, 1.5 hours with pravastatin 
and 3.0 hours with HDA and TDA) consistent with a causal 
relationship. That is, pravastatin levels are affecting HDA 
and TDA levels. Pravastatin may not have been able to af-
fect the levels of CP- I and CP- III in the homozygotes for 
the reduced function allele because CP- I and CP- III may 
have other important routes of elimination. Thus, inhibiting 
residual OATP1B1 activity in individuals who are homozy-
gous for reduced activity of OATP1B1 may have little effect 
on the overall levels of the two CP metabolites. Notably, 
CP- I and CP- III are substrates of both OATP1B1 and 
OATP1B3, whereas HDA and TDA are selective substrates 
of OATP1B1 and also renal transporters, organic anion 
transporter (OAT)1 and OAT3. Thus, CsA, as a nonselective 
inhibitor, would be expected to increase the levels of CP- I 
and CP- III in all patients irrespective of genotype.
Our final finding showed that pravastatin AUC signifi-
cantly correlated with all four biomarkers in all individuals 
irrespectively of SLCO1B1 c.521T>C genotype (Figure 4a). 
The correlation between the endogenous metabolites and 
the exogenous pravastatin gives further strong evidence 
that the endogenous metabolites are useful biomarkers of 
OATP1B1. Future studies are needed to see whether these 
correlations remained significant with larger sample size and 
with other OATP1B1 inhibitors and probe substrates.
There are some limitations in this study. There were only 
two individuals with the SLCO1B1 c.521- CC genotype who 
had plasma samples of sufficient quantity for quantification 
of biomarkers. Future studies with more samples from indi-
viduals homozygous for SLCO1B1 c.521T>C are needed to 
confirm the influence of the polymorphisms on OATP1B1- 
mediated drug–drug or drug–metabolite interactions and 
also to confirm the genetic associations with CP- I and CP- 
III. Another limitation is that other OATP1B1 biomarkers, 
such as bile acids conjugates (sulfates and glucuronide), 
were not measured in this study.39 Thus, extensive com-
parisons of other OATP1B1 biomarkers could not be made. 
Notably, many of these biomarkers, like other drugs, are not 
entirely specific to a single transporter (Table S1). Further 
information and comparisons of other OATP1B1 inhibitors 
and inhibitors of other OATs will provide valuable informa-
tion to guide the use of various types of these biomarkers.
In conclusion, we identified significant associations of the 
major reduced function OATP1B1 polymorphism with CP- I lev-
els. Our studies suggest that SLCO1B1 genotype modulates the 
effect of CsA on pravastatin pharmacokinetics and on the phar-
macokinetics of the OATP1B1 biomarkers tested, although the 
effects were slightly different with each biomarker. Although there 
will be a low prevalence of individuals who are homozygous for 
c.521T>C in most populations, genotyping should be done for 
clarity in the interpretation of the data. Our results suggest that all 
three metabolites, CP- I, HDA, and TDA, have similar sensitivity to 
the OATP1B1/1B3 inhibitor, CsA, and that OATP1B1- Ala174Val 
variant is associated with the levels of these metabolites. 
However, none of these metabolites are substrates of a specific 
transporter (Table S1). Further studies are needed to evaluate the 
effect of the OATP1B1 polymorphism on other clinical biomark-
ers and in the presence of other OATP1B1 inhibitors. Overall, 
these results along with other literature reports strongly support 
the use of HDA/TDA and CP- I as useful biomarkers for clinical 
monitoring of OATP function. A single OATP1B1 biomarker may 
not be sufficient for interpretation of the mechanisms responsible 
for clinical DDIs, and the use of multiple biomarkers is warranted.
Supporting Information. Supplementary information accompa-
nies this paper on the Clinical and Translational Science website (www.
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interaction biomarkers.
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hydroxy pravastatin) alone in volunteers.
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